Compounds > 5-bromo-N-[[[oxo(thiophen-2-yl)methyl]hydrazo]-sulfanylidenemethyl]-2-furancarboxamide

Page last updated: 2024-11-09

5-bromo-N-[[[oxo(thiophen-2-yl)methyl]hydrazo]-sulfanylidenemethyl]-2-furancarboxamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID Source	ID
PubMed CID	1790448
CHEMBL ID	1306438
CHEBI ID	107894

Synonyms (18)

Synonym
REGID_FOR_CID_1790448
5-bromo-n-{[2-(thien-2-ylcarbonyl)hydrazino]carbothioyl}-2-furamide
AN-329/41559355
smr000160627
MLS000324466 ,
5-bromo-n-{[2-(thiophen-2-ylcarbonyl)hydrazinyl]carbonothioyl}furan-2-carboxamide
STK055966
CHEBI:107894
AKOS000493765
5-bromo-n-[(thiophene-2-carbonylamino)carbamothioyl]furan-2-carboxamide
HMS2481H08
CHEMBL1306438
5-bromo-n-[[[oxo(thiophen-2-yl)methyl]hydrazo]-sulfanylidenemethyl]-2-furancarboxamide
5-bromo-n-[(2-thenoylamino)thiocarbamoyl]-2-furamide
cid_1790448
5-bromanyl-n-[(thiophen-2-ylcarbonylamino)carbamothioyl]furan-2-carboxamide
bdbm46891
Q27186236

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

Class	Description
thiophenes	Compounds containing at least one thiophene ring.
aromatic amide	An amide in which the amide linkage is bonded directly to an aromatic system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (23)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	2.8184	0.0447	17.8581	100.0000	AID485294
Chain A, 2-oxoglutarate Oxygenase	Homo sapiens (human)	Potency	3.1623	0.1778	14.3909	39.8107	AID2147
GLS protein	Homo sapiens (human)	Potency	35.4813	0.3548	7.9355	39.8107	AID624170
TDP1 protein	Homo sapiens (human)	Potency	26.1011	0.0008	11.3822	44.6684	AID686978; AID686979
Microtubule-associated protein tau	Homo sapiens (human)	Potency	31.6228	0.1800	13.5574	39.8107	AID1460
Smad3	Homo sapiens (human)	Potency	8.9125	0.0052	7.8098	29.0929	AID588855
apical membrane antigen 1, AMA1	Plasmodium falciparum 3D7	Potency	2.9935	0.7079	12.1943	39.8107	AID720542
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	39.8107	0.0112	12.4002	100.0000	AID1030
regulator of G-protein signaling 4	Homo sapiens (human)	Potency	28.1838	0.5318	15.4358	37.6858	AID504845
nonstructural protein 1	Influenza A virus (A/WSN/1933(H1N1))	Potency	11.2202	0.2818	9.7212	35.4813	AID2326
IDH1	Homo sapiens (human)	Potency	35.4813	0.0052	10.8652	35.4813	AID686970
lysosomal alpha-glucosidase preproprotein	Homo sapiens (human)	Potency	28.1838	0.0366	19.6376	50.1187	AID2100
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	23.1093	0.0041	9.9848	25.9290	AID504444
parathyroid hormone/parathyroid hormone-related peptide receptor precursor	Homo sapiens (human)	Potency	3.1623	3.5481	19.5427	44.6684	AID743266
huntingtin isoform 2	Homo sapiens (human)	Potency	10.0000	0.0006	18.4198	1,122.0200	AID1688
DNA polymerase beta	Homo sapiens (human)	Potency	89.1251	0.0224	21.0102	89.1251	AID485314
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
high affinity choline transporter 1 isoform a	Homo sapiens (human)	IC50 (µMol)	28.8403	0.0003	6.2102	28.8403	AID504840
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
alternatively spliced Trp4	Mus musculus (house mouse)	EC50 (µMol)	5.3080	0.0003	3.3370	10.5907	AID434937
MCOLN3 protein	Homo sapiens (human)	EC50 (µMol)	5.9900	0.7810	3.1603	5.9900	AID1562
corticotropin-releasing hormone receptor 2	Homo sapiens (human)	EC50 (µMol)	12.2000	1.1200	11.5617	36.8000	AID602473
corticotropin releasing factor-binding protein	Homo sapiens (human)	EC50 (µMol)	12.2000	1.1200	11.5617	36.8000	AID602473
transient receptor potential cation channel, subfamily N, member 1	Danio rerio (zebrafish)	EC50 (µMol)	5.4400	1.4700	3.4550	5.4400	AID1682
Mineralocorticoid receptor	Rattus norvegicus (Norway rat)	EC50 (µMol)	5.4400	5.4400	5.4400	5.4400	AID1682
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (18)

Assay ID	Title	Year	Journal	Article
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1880013	Inhibition of bacterial beta-lactamase AmpC at 200 uM using CENTA substrate by colorimetric assay relative to control	2022	Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8	Structure and Mechanism-Guided Design of Dual Serine/Metallo-Carbapenemase Inhibitors.
AID1880012	Inhibition of recombinant bacterial beta-lactamase VIM-2 (26 to 266 residues) expressed in Escherichia coli Lemo21(DE3) at 200 uM using CENTA substrate by colorimetric assay relative to control	2022	Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8	Structure and Mechanism-Guided Design of Dual Serine/Metallo-Carbapenemase Inhibitors.
AID1880009	Inhibition of bacterial beta-lactamase CTX-M-15 at 200 uM CENTA substrate by colorimetric assay relative to control	2022	Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8	Structure and Mechanism-Guided Design of Dual Serine/Metallo-Carbapenemase Inhibitors.
AID1880010	Inhibition of bacterial beta-lactamase KPC-2 at 200 uM using CENTA substrate by colorimetric assay relative to control	2022	Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8	Structure and Mechanism-Guided Design of Dual Serine/Metallo-Carbapenemase Inhibitors.
AID1880011	Inhibition of recombinant bacterial beta-lactamase NMD-1 (28 to 270 residues) at 200 uM using CENTA substrate by colorimetric assay relative to control	2022	Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8	Structure and Mechanism-Guided Design of Dual Serine/Metallo-Carbapenemase Inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (16.67)	29.6817
2010's	3 (50.00)	24.3611
2020's	2 (33.33)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.41 (24.57)
Research Supply Index	1.95 (2.92)
Research Growth Index	4.36 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.41)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (16.67%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (83.33%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Condition	Indicated	Relationship Strength	Studies	Trials
Innate Inflammatory Response [description not available]	0	2.05	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	2.05	1	0